- Page 1 and 2:
METHODS IN MOLECULAR BIOLOGY 360 T
- Page 3 and 4:
M E T H O D S I N M O L E C U L A R
- Page 5 and 6:
© 2007 Humana Press Inc. 999 River
- Page 7 and 8:
vi Preface get. Approaches to targe
- Page 9 and 10:
viii Contents 10 Transgenic Animal
- Page 11 and 12:
x Contributors SAHOHIME MATSUMOTO
- Page 13 and 14:
xii Contents of Volume 2 12 Validat
- Page 15 and 16:
2 Sioud disease pathogenesis and pe
- Page 17 and 18:
4 Sioud A more fruitful approach fo
- Page 19 and 20:
6 Sioud both transient and permanen
- Page 21 and 22:
8 Sioud serum biomarkers. This syne
- Page 23 and 24:
10 Sioud Fig. 2. Schematic of targe
- Page 25 and 26:
12 Sioud 13. Magin, T. M. (1998) Le
- Page 28 and 29:
Harnessing the Human Genome 15 The
- Page 30 and 31:
Harnessing the Human Genome 17 Fig.
- Page 32 and 33:
Harnessing the Human Genome 19 Fig.
- Page 34 and 35:
Harnessing the Human Genome 21 Fig.
- Page 36 and 37:
Harnessing the Human Genome 23 The
- Page 38 and 39:
Harnessing the Human Genome 25 Fig.
- Page 40 and 41:
Harnessing the Human Genome 27 repr
- Page 42 and 43:
Harnessing the Human Genome 29 14.
- Page 44:
Harnessing the Human Genome 31 45.
- Page 47 and 48:
34 Imoto et al. (4,5), and Bayesian
- Page 49 and 50:
36 Imoto et al. 2. Materials Two ty
- Page 51 and 52:
38 Imoto et al. Fig. 3. Graphical v
- Page 53 and 54:
40 Imoto et al. Fig. 5. Result of t
- Page 55 and 56:
42 Imoto et al. p(D |G) = ∫ p(D,
- Page 57 and 58:
44 Imoto et al. β k (k = 1,…,q j
- Page 59 and 60:
46 Imoto et al. Fig. 7. Partial res
- Page 61 and 62:
48 Imoto et al. Fig. 8. Strategy to
- Page 63 and 64:
50 Imoto et al. Fig. 9. (continued)
- Page 65 and 66:
52 Imoto et al. Table 3 List of Roo
- Page 67 and 68:
54 Imoto et al. 5. De Hoon, M. J. L
- Page 69 and 70:
56 Imoto et al. 39. Kamimura, T., S
- Page 71 and 72:
58 Beaty et al. cytotoxic drugs and
- Page 73 and 74:
60 Beaty et al. Fig. 1. Principles
- Page 75 and 76:
62 Beaty et al. oligonucleotide mic
- Page 77 and 78:
64 Beaty et al. 3. The 12% polyacry
- Page 79 and 80:
66 Beaty et al. 2.3.3. Protein Stai
- Page 81 and 82:
68 Beaty et al. 3.1.3. Labeling of
- Page 83 and 84:
70 Beaty et al. 1 µL of the anneal
- Page 85 and 86:
72 Beaty et al. 4. Phenol:cholorfor
- Page 87 and 88:
74 Beaty et al. 19. Wash twice with
- Page 89 and 90:
76 Beaty et al. The Following Volum
- Page 91 and 92:
78 Beaty et al. using a protein ass
- Page 93 and 94:
80 Beaty et al. 6. Shake the gel fo
- Page 95 and 96:
82 Beaty et al. Fig. 2. Preparation
- Page 97 and 98:
84 Beaty et al. search in. A widely
- Page 99 and 100:
86 Beaty et al. 3. Kern, S. E., Hru
- Page 101 and 102:
88 Beaty et al. 34. Peters, D. G.,
- Page 104 and 105:
5 Molecular Classification of Breas
- Page 106 and 107:
Molecular Profiling of Breast Cance
- Page 108 and 109:
Molecular Profiling of Breast Cance
- Page 110 and 111:
Fig. 2. (Continued) the right ident
- Page 112 and 113:
Molecular Profiling of Breast Cance
- Page 114 and 115:
Molecular Profiling of Breast Cance
- Page 116 and 117:
Molecular Profiling of Breast Cance
- Page 118 and 119:
Molecular Profiling of Breast Cance
- Page 120 and 121:
Molecular Profiling of Breast Cance
- Page 122 and 123:
Molecular Profiling of Breast Cance
- Page 124 and 125:
Molecular Profiling of Breast Cance
- Page 126 and 127:
Molecular Profiling of Breast Cance
- Page 128 and 129:
6 Discovery of Differentially Expre
- Page 130 and 131:
Gene Target Discovery 117 In the fi
- Page 132 and 133:
Gene Target Discovery 119 sequences
- Page 134 and 135:
Gene Target Discovery 121 There is
- Page 136 and 137:
Gene Target Discovery 123 digestion
- Page 138 and 139:
Gene Target Discovery 125 Fig. 1. P
- Page 140 and 141: Gene Target Discovery 127 5. Sargen
- Page 142: Gene Target Discovery 129 41. Berry
- Page 145 and 146: 132 Matsumoto, Miyagishi, and Taira
- Page 147 and 148: 134 Matsumoto, Miyagishi, and Taira
- Page 149 and 150: 136 Matsumoto, Miyagishi, and Taira
- Page 151 and 152: 138 Matsumoto, Miyagishi, and Taira
- Page 153 and 154: 140 Matsumoto, Miyagishi, and Taira
- Page 155 and 156: 142 Matsumoto, Miyagishi, and Taira
- Page 157 and 158: 144 Fig. 1. The ribozyme-expression
- Page 159 and 160: 146 Sano and Taira 5. 10X L (low-sa
- Page 161 and 162: 148 Sano and Taira ribozymes may cl
- Page 163 and 164: 150 Fig. 3. A system for the identi
- Page 165 and 166: 152 Sano and Taira 4. Notes 1. We r
- Page 168 and 169: 9 Production of siRNA- and cDNA-Tra
- Page 170 and 171: Transfected Cell Arrays 157 Fig. 1.
- Page 172 and 173: Transfected Cell Arrays 159 2. The
- Page 174: Transfected Cell Arrays 161 5. Simp
- Page 177 and 178: 164 Houdebine Fig. 1. Different met
- Page 179 and 180: 166 Houdebine concentrations become
- Page 181 and 182: 168 Houdebine Fig. 2. Major methods
- Page 183 and 184: 170 Houdebine integrate into the me
- Page 185 and 186: 172 Houdebine 2.2.3. Knock-In Into
- Page 187 and 188: 174 Houdebine as insulators. The co
- Page 189: 176 Houdebine Fig. 5. Different met
- Page 193 and 194: 180 Houdebine contribute to generat
- Page 195 and 196: 182 Houdebine Fig.7. Example of a v
- Page 197 and 198: 184 Houdebine more extensively. Tra
- Page 199 and 200: 186 Houdebine and stroma. Several o
- Page 201 and 202: 188 Houdebine explained at the mole
- Page 203 and 204: 190 Houdebine of the intestinal epi
- Page 205 and 206: 192 Houdebine interference of the g
- Page 207 and 208: 194 Houdebine 17. Whitelaw, C. B. A
- Page 209 and 210: 196 Houdebine 51. Bell, A. C., West
- Page 211 and 212: 198 Houdebine 86. Carmichael, G. G.
- Page 213 and 214: 200 Houdebine 121. Pailhoux, E., Vi
- Page 215 and 216: 202 Houdebine 156. Auerbach, A. B.,
- Page 217 and 218: 204 Vijayaraj, Söhl, and Magin 1.
- Page 219 and 220: 206 Vijayaraj, Söhl, and Magin Fig
- Page 221 and 222: 208 Vijayaraj, Söhl, and Magin fil
- Page 223 and 224: 210 Table 1 Orthologous Human and M
- Page 225 and 226: 212 Table 2 Orthologous Human and M
- Page 227 and 228: 214 Vijayaraj, Söhl, and Magin ulc
- Page 229 and 230: 216 Vijayaraj, Söhl, and Magin of
- Page 231 and 232: 218 Vijayaraj, Söhl, and Magin sug
- Page 233 and 234: 220 Vijayaraj, Söhl, and Magin abs
- Page 235 and 236: 222 Vijayaraj, Söhl, and Magin 1.2
- Page 237 and 238: 224 Vijayaraj, Söhl, and Magin Fig
- Page 239 and 240: 226 Vijayaraj, Söhl, and Magin gen
- Page 241 and 242:
228 Vijayaraj, Söhl, and Magin the
- Page 243 and 244:
230 Vijayaraj, Söhl, and Magin f.
- Page 245 and 246:
232 Vijayaraj, Söhl, and Magin 3.
- Page 247 and 248:
234 Vijayaraj, Söhl, and Magin b.
- Page 249 and 250:
236 Vijayaraj, Söhl, and Magin 4.
- Page 251 and 252:
238 Vijayaraj, Söhl, and Magin 1.
- Page 253 and 254:
240 Vijayaraj, Söhl, and Magin alt
- Page 255 and 256:
242 Table 3 Time Schedule For Aggre
- Page 257 and 258:
244 Vijayaraj, Söhl, and Magin 7.
- Page 259 and 260:
246 Vijayaraj, Söhl, and Magin 37.
- Page 261 and 262:
248 Vijayaraj, Söhl, and Magin 68.
- Page 263 and 264:
250 Vijayaraj, Söhl, and Magin 101
- Page 266 and 267:
12 The HUVEC/Matrigel Assay An In V
- Page 269 and 270:
256 Skovseth, Küchler, and Haralds
- Page 271 and 272:
258 Skovseth, Küchler, and Haralds
- Page 273 and 274:
260 Skovseth, Küchler, and Haralds
- Page 275 and 276:
262 Skovseth, Küchler, and Haralds
- Page 277 and 278:
264 Skovseth, Küchler, and Haralds
- Page 279 and 280:
266 Skovseth, Küchler, and Haralds
- Page 281 and 282:
268 Skovseth, Küchler, and Haralds
- Page 283 and 284:
270 Iversen and Sørensen witnessed
- Page 285 and 286:
272 Iversen and Sørensen Fig. 1. P
- Page 287 and 288:
274 Iversen and Sørensen the core
- Page 290 and 291:
14 An Overview of the Immune System
- Page 292 and 293:
Overview of Immune System 279 diffe
- Page 294 and 295:
Overview of Immune System 281 Fig.
- Page 296 and 297:
Overview of Immune System 283 then
- Page 298 and 299:
Overview of Immune System 285 expre
- Page 300 and 301:
Overview of Immune System 287 Once
- Page 302 and 303:
Overview of Immune System 289 solub
- Page 304 and 305:
Overview of Immune System 291 amino
- Page 306 and 307:
Overview of Immune System 293 (unre
- Page 308 and 309:
Overview of Immune System 295 Fig.
- Page 310 and 311:
Overview of Immune System 297 the c
- Page 312 and 313:
Overview of Immune System 299 (44).
- Page 314 and 315:
Overview of Immune System 301 demon
- Page 316 and 317:
Overview of Immune System 303 Fig.
- Page 318 and 319:
Overview of Immune System 305 Fig.
- Page 320 and 321:
Overview of Immune System 307 some
- Page 322 and 323:
Overview of Immune System 309 sera
- Page 324 and 325:
Overview of Immune System 311 Fig.
- Page 326 and 327:
Overview of Immune System 313 measu
- Page 328 and 329:
Overview of Immune System 315 42. H
- Page 330 and 331:
Overview of Immune System 317 74. D
- Page 332 and 333:
15 Potential Target Antigens for Im
- Page 334 and 335:
Tumor Antigen Discovery 321 develop
- Page 336 and 337:
Tumor Antigen Discovery 323 panel b
- Page 338 and 339:
Tumor Antigen Discovery 325 16. Joc
- Page 340 and 341:
16 Identification of Tumor Antigens
- Page 342 and 343:
Immunoproteomics 329 by “shot gun
- Page 344 and 345:
Immunoproteomics 331 isoelectric fo
- Page 346 and 347:
Immunoproteomics 333 3. 2D-PAGE is
- Page 348 and 349:
17 Protein Arrays A Versatile Toolb
- Page 350 and 351:
Protein Arrays 337 Table 1 Classifi
- Page 352 and 353:
Protein Arrays 339 fractions from c
- Page 354 and 355:
Protein Arrays 341 combinatorial sc
- Page 356 and 357:
Protein Arrays 343 The ideal proteo
- Page 358 and 359:
Protein Arrays 345 18. Cekaite, H.
- Page 360 and 361:
Protein Arrays 347 49. Yuko Kawahas
- Page 362 and 363:
Index 349 Index A Acetyl-CoA carbox
- Page 364 and 365:
Index 351 conditional by using FRT
- Page 366 and 367:
Index 353 Recombinant tumor antigen